Preview

Rational Pharmacotherapy in Cardiology

Advanced search

ACETYLSALICYLIC ACID: CONTROVERSIAL AND OUTSTANDING ISSUES

https://doi.org/10.20996/1819-6446-2013-9-4-439-443

Full Text:

Abstract

Review of current ideas about the role of acetylsalicylic acid (ASA) in the primary prevention of cardiovascular disease is presented. Data on reduction in malignant neoplasms incidence rate in long-term use of the drug, as well as prospects for further study of ASA in the primary prevention are considered.

About the Author

E. N. Dankovtseva
Educational Scientific Medical Centre, Administrative Department of the President of the Russian Federation, City Clinical Hospital № 51, Moscow
Russian Federation


References

1. Juul-Moller S., Edvardsson N., Jahnmatz B., et al. Double-blind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectoris. Lancet 1992; 340:1421-5.

2. Lewis HD Jr., Davis JW., Archibald DG et al. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina: results of a Veterans Administration Cooperative Study. N Engl J Med 1983; 309:396-403.

3. Cairns JA., Gent M., Singer J. et al. Aspirin, sulfinpyrazone, or both in unstable angina: results of a Canadian multicenter trial. N Engl J Med 1985; 313:1369-75.

4. Theroux P., Ouimet H., McCans J. et al. Aspirin, heparin, or both to treat acute unstable angina. N Engl J Med 1988; 319:1105-11.

5. The RISC Group. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet 1990; 336:827-30.

6. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988; 2:349-60.

7. Baigent C., Blackwell L., Collins R. et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009; 373:1849-60.

8. The Medical Research Council’s General Practice Research Framework. Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. Lancet 1998; 351:233-41.

9. Hansson L., Zanchetti A., Carruthers SG. et al; HOT Study Group. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet 1998; 351(9118):1755 -62.

10. De Gaetano G; Collaborative Group of the Primary Prevention Project. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomized trial in general practice. Lancet 2001; 357:89-95.

11. Belch J., MacCuish A., Campbell I. et al. The Prevention of Progression of Arterial Disease and Diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ 2008; 337:1-10.

12. Ogawa H., Nakayama M., Morimoto T. et al; Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes (JPAD) Trial Investigators. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA 2008; 300(18):2134-41.

13. Fowkes FG., Price JF., Stewart MC. et al; Aspirin for Asymptomatic Atherosclerosis Trialists. Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial. JAMA 2010; 303(9):841-8.

14. Peto R., Gray R., Collins R. et al. Randomised trial of prophylactic daily aspirin in British male doctors. BMJ 1988; 296:313-6.

15. Steering Committee of the Physicians’ Health Study Research Group. Final report on the aspirin component of the ongoing Physicians’ Health Study. N Engl J Med 1989; 321(3):129-35.

16. Ridker PM., Cook NR., Lee IM. et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 2005; 352(13):1293-304.

17. Raju N., Sobieraj-Teague M., Hirsh J. et al. Effect of aspirin on mortality in primary prevention of cardiovascular disease. Am J Med 2011; 124(7):621-9.

18. Bartolucci AA., Tendera M., Howard G. Meta-analysis of multiple primary prevention trials of cardiovascular events using aspirin. Am J Cardiol 2011; 107:1796-801.

19. Patrono C. Low-dose aspirin in primary prevention: cardioprotection, chemoprevention, both, or neither? European Heart Journal. Eur Heart J 2013 Jun 14. [Epub ahead of print]

20. Calvin AD., Aggarwal NR., Murad MH. et al. Aspirin for the primary prevention of cardiovascular events: a systematic review and meta-analysis comparing patients with and without diabetes. Diabetes Care 2009; 32:2300-06.

21. Okada S., Morimoto T., Ogawa H. et al. Differential Effect of Low-Dose Aspirin for Primary Prevention of Atherosclerotic Events in Diabetes Management. Diabetes Care 2011; 34:1277-83.

22. Lanas A., Perez-Aisa MA., Feu F. et al. A nationwide study of mortality associated with hospital admission due to severe gastrointestinal events and those associated with non-steroidal anti-inflammatory drug use. Am J Gastroenterol 2005:100:1685-93.

23. Calonge N., Petitti DB., DeWitt TG. et al. Aspirin for the prevention of cardiovascular disease: US Preventive Services Task Force recommendation statement. Ann Intern Med 2009; 150:396-404.

24. Vandvik PO., Lincoff AM., Gore JM. et al. Primary and secondary prevention of cardiovascular disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012: 141(2) (suppl): e637S-e668S.

25. Perk J., De Backer G., Gohlke H. et al. European Guidelines on cardiovascular disease prevention in clin- ical practice (version 2012): The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J 2012; 33:1635-701.

26. Pignone M., Alberts MJ., Colwell JA. et al. Aspirin for primary prevention of cardiovascular events in people with diabetes: a position statement of the American Diabetes Association, a scientific statement of the American Heart Association, and an expert consensus document of the American College of Cardiology Foundation. Circulation 2010; 121:2694-701.

27. Flossman E., Rothwell PM. Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet. 2007; 369:1603-1613.

28. Rothwell PM., Wilson M., Elwin CE. et al. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet 2010; 376(9754):1741-50.

29. Rothwell PM., Fowkes FG., Belch JF. et al. Effect of daily aspirin on long-term risk of death due to can- cer: analysis of individual patient data from randomised trials. Lancet 2011; 377(9759): 31-41.

30. Rothwell PM., Price JF., Fowkes FG. et al. Short-term effects of daily aspirin on cancer incidence, mortality and nonvascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet 2012; 379:1602-12.

31. Thun M., Henley S., Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents: mecha- nistic, pharmacologic, and clinical issues. J Natl Cancer Inst 2002; 94: 252-66

32. Thun MJ., Jacobs EJ., Patrono C. The role of aspirin in cancer prevention. Nat Rev Clin Oncol 2012; 3:259-67.

33. Patrono C., Patrignani P., Garcia Rodriguez LA. Cyclooxygenase-selective inhibition of prostanoid formation: transducing biochemical selectivity into clinical read-outs. J Clin Invest 2001; 108:7-13.

34. A Study of Cardiovascular Events in Diabetes (ASCEND). http://www.ctsu.ox. ac.uk/ascend.

35. De Berardis G., Sacco M., Evangelista V. et al; ACCEPT-D Study Group. Aspirin and Simvastatin Combination for Cardiovascular Events Prevention Trial in Diabetes (ACCEPT-D): design of a randomized study of the efficacy of low-dose aspirin in the prevention of cardiovascular events in subjects with diabetes mellitus treated with statins. Trials 2007; 8:21.

36. Nelson MR., Reid CM., Ames DA. et al. Feasibility of conducting a primary prevention trial of low-dose aspirin for major adverse cardiovascular events in older people in Australia: results from ASPirin in Reducing Events in the Elderly (ASPREE) pilot study. Med J Aust 2008; 189:105-9.

37. Aspirin to Reduce Risk of Initial Vascular Events (ARRIVE). http://www.arrivestudy.com.

38. Vertkin AL., Aristarhova O., Adonina E.V. et al. Safety and pharmacoeconomic efficacy of different drugs of acetylsalicylic acid in patients with coronary artery disease. Russian Journal of Medicine 2009; 17 (8): 570-575. Russian (Верткин А.Л., Аристархова О.Ю., Адонина Е.В. и др. Безопасность и фармакоэкономическая эффективность применения различных препаратов ацетилсалициловой кислоты у пациентов с ИБС. Русский Медицинский Журнал 2009; 17(8): 570-575).


For citation:


Dankovtseva E.N. ACETYLSALICYLIC ACID: CONTROVERSIAL AND OUTSTANDING ISSUES. Rational Pharmacotherapy in Cardiology. 2013;9(4):439-443. (In Russ.) https://doi.org/10.20996/1819-6446-2013-9-4-439-443

Views: 798


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)